Page last updated: 2024-12-11
vaxfectin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
vaxfectin: used in formulating tuberculosis DNA vaccines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9963916 |
| MeSH ID | M0432881 |
Synonyms (8)
| Synonym |
|---|
| vaxfectin |
| 370108-99-9 |
| aminopropyl-dimethyl-myristoyleyloxy-propanaminium bromide-diphytanoylphosphatidyl-ethanolamine |
| HY-142998 |
| [(2r)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-(3,7,11,15-tetramethylhexadecanoyloxy)propyl] 3,7,11,15-tetramethylhexadecanoate;3-aminopropyl-[2,3-bis[(z)-tetradec-9-enoxy]propyl]-dimethylazanium;bromide |
| 1-propanaminium, n-(3-aminopropyl)-n,n-dimethyl-2,3-bis[(9z)-9-tetradecenyloxy]-, bromide, mixt. with (1r)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl bis(3,7,11,15-tetramethylhexadecanoate) |
| STARBLD0002272 |
| CS-0374782 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "All doses were well tolerated without vaccine-related serious adverse events or discontinuations." | ( Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Al-Ibrahim, MS; Belshe, RB; Boutsaboualoy, S; Chaplin, JA; Chu, AH; Dunne, CE; Fisher, CL; Kabongo, ML; Kitt, ER; Moss, RB; Reyes, LR; Rolland, AP; Rusalov, D; Smith, LR; Steigbigel, R; Wloch, MK; Ye, M, 2010) | 0.36 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " By using a novel, lipid-based adjuvant, Vaxfectin, to attract immune cells to the immunization site, in combination with an antigen-chemokine DNA construct designed to target antigen to immature dendritic cells, we elicited a humoral immune response that provided sterilizing immunity to malaria challenge in a mouse model system." | ( Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities. Biragyn, A; Espinosa, DA; Luo, K; Markham, RB; Zavala, F; Zhang, H, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (24)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (8.00%) | 5.53% |
| Reviews | 1 (4.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (88.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||